Female hirsutism: pathophysiological considerations and therapeutic implications.
D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000378:metabolism; D000311:Adrenal Glands / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000037:antagonists & inhibitors; D000726:Androgen Antagonists / Q000627:therapeutic use; D000728:Androgens / Q000378:metabolism; D000735:Androstenedione / Q000032:analysis; D001693:Biological Transport, Active; D001798:Blood Proteins / Q000378:metabolism; D003534:Cyproterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D003687:Dehydroepiandrosterone / Q000031:analogs & derivatives / Q000032:analysis; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone; D013196:Dihydrotestosterone / Q000378:metabolism; D005260:Female; D006628:Hirsutism / Q000503:physiopathology* / Q000628:therapy; D006801:Humans; D007700:Kinetics; D010053:Ovary / Q000378:metabolism; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D012867:Skin / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use
D000726:Androgen Antagonists; D000728:Androgens; D001798:Blood Proteins; D012738:Sex Hormone-Binding Globulin; D013196:Dihydrotestosterone; D013148:Spironolactone; D000735:Androstenedione; D003687:Dehydroepiandrosterone; D017373:Cyproterone Acetate; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone; D000324:Adrenocorticotropic Hormone; D003534:Cyproterone; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase